Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has scheduled its second quarter 2025 financial results announcement for August 11, 2025.

The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Interested parties can register for the video call and access the webcast through a provided link or by visiting the "News and Events" section in the Investors area of Kymera's website.

WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2025 financial results on August 11, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor and Media Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

When will Kymera Therapeutics (KYMR) report Q2 2025 earnings?

Kymera Therapeutics will report its Q2 2025 financial results on August 11, 2025.

What time is Kymera Therapeutics' Q2 2025 earnings call?

The video conference call and webcast will be held at 8:30 a.m. ET on August 11, 2025.

How can investors access Kymera Therapeutics' Q2 2025 earnings call?

Investors can access the video call and webcast by registering through the provided link or visiting the 'News and Events' section in the Investors area of www.kymeratx.com.

What type of medicines is Kymera Therapeutics (KYMR) developing?

Kymera Therapeutics is developing a new class of oral small molecule degrader medicines focused on treating immunological diseases.